PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Abroad (travel likely)RecruitingPHASE1
Conditions
NF1 Mutation · Neurofibroma Plexiform · Neurofibroma, Plexiform · Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) · Neurofibromatosis Type 1 (NF1)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact: Principal Investigator (Rebecca Brown, MD PhD)Royal North Shore Hospital, St Leonards, New South Wales, Australia
Contact: Study coordinator (Yemima Berman, BMBS FRACP BSc Hons PhD Med) · NSLHD-clinicalgenetics@health.nsw.gov.au · +61 2 9463 1727Contact: Study coordinator (Nanette Lacson, Bachelor in Nursing) · NSLHD-clinicalgenetics@health.nsw.gov.au · +61 2 9926 4775Contact: Principal Investigator (Yemima Berman, BMBS FRACP BSc Hons PhD Med.)Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Contact: Study coordinator (Monc A Neuro Oncology Team) · PCCTU.MoncA@petermac.org · +61 3 8559 5000Contact: Principal Investigator (James Whittle, MBBS, FRACP)Asan Medical Center, Seoul, South Korea
Contact: Study coordinator (Beom Hee Lee, PhD Medicine) · beomhee.lee@amc.seoul.kr · +82-2-3010-7358Contact: Principal Investigator (Beom Hee Lee, PhD Medicine)Severance Hospital, Yonsei University Health System, Sinchŏn-dong, South Korea
Contact: Principal Investigator (Ji Young Oh, PhD Medicine)
Study leads
Tiago R Marques, MD
Study Director
Pasithea Therapeutics Corp.